SRT2104: Clinical Trials

11 completed, 1 withdrawn. 9 Phase 1, 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	9	Completed 8, Withdrawn 1
Phase 2	3	Completed 3

Follow SRT2104: new trials by email Literature Review of SRT2104 trials Research Report on SRT2104

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis SRT2104 - Colitis, Ulcerative	Phase 1	Completed	Sirtris, a GSK Company	17	2012-02-13	2017-06-01
A Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers Placebo, SRT2104 - Healthy Volunteer, Atrophy, Muscular	Phase 1	Withdrawn	GlaxoSmithKline		2011-01-01	2015-04-17
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis Placebo, SRT2104 - Psoriasis	Phase 2	Completed	Sirtris, a GSK Company	40	2010-06-07	2017-10-13
A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus Placebo, SRT2104 - Diabetes Mellitus, Type 2	Phase 1	Completed	Sirtris, a GSK Company	38	2010-05-28	2017-06-20
A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus Placebo, SRT2104 - Diabetes Mellitus, Type 2	Phase 2	Completed	GlaxoSmithKline	86	2010-03-03	2017-04-25
Effect of SRT2104 on Endotoxin-induced Inflammation Placebo, SRT2104 - Sepsis	Phase 1	Completed	GlaxoSmithKline	41	2009-12-09	2017-06-22
A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days Placebo, SRT2104 - Atrophy, Muscular	Phase 1	Completed	GlaxoSmithKline	24	2009-10-01	2017-06-16
Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects SRT2104, Placebo - Diabetes Mellitus, Type 2	Phase 2	Completed	Sirtris, a GSK Company	227	2009-08-19	2018-07-13
Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers Placebo, 0.25g SRT2104, Prednisolone - Pulmonary Disease, Chronic Obstructive	Phase 1	Completed	GlaxoSmithKline	20	2009-04-06	2017-07-07
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers SRT2104, Placebo - Diabetes Mellitus, Type 2	Phase 1	Completed	GlaxoSmithKline	10	2009-03-23	2017-07-07
A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers 0.5g SRT2104 - Diabetes Mellitus, Type 2	Phase 1	Completed	Sirtris, a GSK Company	20	2009-01-20	2017-07-21
A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers SRT2104, Placebo - Diabetes Mellitus, Type 2, Healthy Volunteer	Phase 1	Completed	Sirtris, a GSK Company	43	2008-05-01	2017-05-30

Conditions studied

Diabetes Mellitus, Type 2 (6)  ·  Muscular Atrophy (2)  ·  Colitis, Ulcerative (1)  ·  Psoriasis (1)  ·  Pulmonary Disease, Chronic Obstructive (1)  ·  Sepsis (1)

Sponsors

GlaxoSmithKline (6)  ·  Sirtris, a GSK Company (6)

Countries

United Kingdom (7)  ·  United States (2)  ·  Bulgaria (1)  ·  Estonia (1)  ·  Germany (1)  ·  Hungary (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)  ·  Ukraine (1)

Results publications

PMID 23770971, PMID 25978169, PMID 26556603, PMID 26595549, PMID 27239324, PMID 28912956